Assessment of New Molecular Entities Approved for Cancer Treatment in 2020

被引：4

作者：

Smith, Claire E. P. ^{[1
]}

Prasad, Vinay ^{[2
,3
]}

机构：

[1] Boston Univ, Sch Med, Hematol & Med Oncol, Boston, MA 02118 USA

[2] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA

[3] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA

来源：

JAMA NETWORK OPEN | 2021年 / 4卷 / 05期

关键词：

D O I：

10.1001/jamanetworkopen.2021.12558

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 6 条

[1]

Carpenter D, 2011, NEW ENGL J MED, V365, DOI [10.1056/nejmp1107201, 10.1056/NEJMp1107201]

[2] A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology [J].

Haslam, Alyson ;

Hey, Spencer P. ;

Gill, Jennifer ;

Prasad, Vinay .

EUROPEAN JOURNAL OF CANCER, 2019, 106 :196-211

[3]

Perez S., 2020, TECHCRUNCH COM

[4]

U.S. Food & Drug Administration, 2020, FDA Approves First Treatment for COVID-19

[5]

US Food and Drug Administration, US FOOD DRUG ADM HEM

[6] Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology Survey [J].

Waterhouse, David M. ;

Harvey, R. Donald ;

Hurley, Patricia ;

Levit, Laura A. ;

Kim, Edward S. ;

Klepin, Heidi D. ;

Mileham, Kathryn Finch ;

Nowakowski, Grzegorz ;

Schenkel, Caroline ;

Davis, Courtney ;

Bruinooge, Suanna S. ;

Schilsky, Richard L. .

JCO ONCOLOGY PRACTICE, 2020, 16 (07) :417-+

← 1 →